58 related articles for article (PubMed ID: 26666467)
1. Artificial neural network-based pharmacogenomic algorithm for warfarin dose optimization.
Pavani A; Naushad SM; Kumar RM; Srinath M; Malempati AR; Kutala VK
Pharmacogenomics; 2016; 17(2):121-31. PubMed ID: 26666467
[TBL] [Abstract][Full Text] [Related]
2. Gene-based warfarin dosing compared with standard of care practices in an orthopedic surgery population: a prospective, parallel cohort study.
McMillin GA; Melis R; Wilson A; Strong MB; Wanner NA; Vinik RG; Peters CL; Pendleton RC
Ther Drug Monit; 2010 Jun; 32(3):338-45. PubMed ID: 20386359
[TBL] [Abstract][Full Text] [Related]
3. Mechanistic insights into the effect of CYP2C9*2 and CYP2C9*3 variants on the 7-hydroxylation of warfarin.
Pavani A; Naushad SM; Stanley BA; Kamakshi RG; Abinaya K; Amaresh Rao M; Uma A; Kutala VK
Pharmacogenomics; 2015; 16(4):393-400. PubMed ID: 25823787
[TBL] [Abstract][Full Text] [Related]
4. A proposal for an individualized pharmacogenetics-based warfarin initiation dose regimen for patients commencing anticoagulation therapy.
Avery PJ; Jorgensen A; Hamberg AK; Wadelius M; Pirmohamed M; Kamali F;
Clin Pharmacol Ther; 2011 Nov; 90(5):701-6. PubMed ID: 22012312
[TBL] [Abstract][Full Text] [Related]
5. Prospective dosing of warfarin based on cytochrome P-450 2C9 genotype.
Voora D; Eby C; Linder MW; Milligan PE; Bukaveckas BL; McLeod HL; Maloney W; Clohisy J; Burnett RS; Grosso L; Gatchel SK; Gage BF
Thromb Haemost; 2005 Apr; 93(4):700-5. PubMed ID: 15841315
[TBL] [Abstract][Full Text] [Related]
6. Relationship of S/R warfarin ratio with CYP2C9 genotypes in Pakistani population.
Qayyum A; Najmi MH; Raza SI; Rajput TA; Naveed AK
Pak J Pharm Sci; 2019 Jul; 32(4):1581-1588. PubMed ID: 31608877
[TBL] [Abstract][Full Text] [Related]
7. Interindividual variability in sensitivity to warfarin--Nature or nurture?
Loebstein R; Yonath H; Peleg D; Almog S; Rotenberg M; Lubetsky A; Roitelman J; Harats D; Halkin H; Ezra D
Clin Pharmacol Ther; 2001 Aug; 70(2):159-64. PubMed ID: 11503010
[TBL] [Abstract][Full Text] [Related]
8. CYP2C9 Genotype-Dependent Warfarin Pharmacokinetics: Impact of CYP2C9 Genotype on R- and S-Warfarin and Their Oxidative Metabolites.
Flora DR; Rettie AE; Brundage RC; Tracy TS
J Clin Pharmacol; 2017 Mar; 57(3):382-393. PubMed ID: 27539372
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.
Albrecht D; Turakhia MP; Ries D; Marbury T; Smith W; Dillon D; Milner PG; Midei MG
Thromb Haemost; 2017 Nov; 117(11):2026-2033. PubMed ID: 28933798
[TBL] [Abstract][Full Text] [Related]
10. The influence of (R)- and (S)-warfarin, vitamin K and vitamin K epoxide upon warfarin anticoagulation.
Kamali F; Edwards C; Butler TJ; Wynne HA
Thromb Haemost; 2000 Jul; 84(1):39-42. PubMed ID: 10928467
[TBL] [Abstract][Full Text] [Related]
11. Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin.
Kamali F; Khan TI; King BP; Frearson R; Kesteven P; Wood P; Daly AK; Wynne H
Clin Pharmacol Ther; 2004 Mar; 75(3):204-12. PubMed ID: 15001972
[TBL] [Abstract][Full Text] [Related]
12. CYP2C9 Polymorphism and Unstable Anticoagulation with Warfarin in Patients Within the First 3 Months Following Heart Valve Replacement.
Wypasek E; Cieśla M; Suder B; Janik Ł; Sadowski J; Undas A
Adv Clin Exp Med; 2015; 24(4):607-14. PubMed ID: 26469104
[TBL] [Abstract][Full Text] [Related]
13. A Bayesian dose-individualization method for warfarin.
Wright DF; Duffull SB
Clin Pharmacokinet; 2013 Jan; 52(1):59-68. PubMed ID: 23329393
[TBL] [Abstract][Full Text] [Related]
14. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
Siddiqi A; Khan DA; Khan FA; Naveed AK
Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetic-guided Warfarin Dosing Algorithm in African-Americans.
Alzubiedi S; Saleh MI
J Cardiovasc Pharmacol; 2016 Jan; 67(1):86-92. PubMed ID: 26355760
[TBL] [Abstract][Full Text] [Related]
17. S-Warfarin Limited Sampling Models to Estimate Area Under the Concentration Versus Time Curve for Cytochrome P450 2C9 Baseline Activity and After Induction.
Chang AT; Bertino JS; Nafziger AN; Kashuba AD; Turpault S; Lewis LD; Ma JD
Ther Drug Monit; 2016 Jun; 38(3):383-7. PubMed ID: 26818625
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel individualized warfarin dose algorithm based on a population pharmacokinetic model with improved prediction accuracy for Chinese patients after heart valve replacement.
Zhu YB; Hong XH; Wei M; Hu J; Chen X; Wang SK; Zhu JR; Yu F; Sun JG
Acta Pharmacol Sin; 2017 Mar; 38(3):434-442. PubMed ID: 28216623
[TBL] [Abstract][Full Text] [Related]
19. Development of a system to support warfarin dose decisions using deep neural networks.
Lee H; Kim HJ; Chang HW; Kim DJ; Mo J; Kim JE
Sci Rep; 2021 Jul; 11(1):14745. PubMed ID: 34285309
[TBL] [Abstract][Full Text] [Related]
20. Validation of an algorithm to predict decline in INR following warfarin cessation in patients undergoing invasive procedures.
Kampouraki E; Wynne H; Avery P; Kamali F
J Thromb Thrombolysis; 2020 May; 49(4):630-635. PubMed ID: 31848875
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
